The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system

High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes

(2014) Canan Alhan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes

(2014) Canan Alhan et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia

(2014) M. G. Della Porta et al.   HAEMATOLOGICA

Molecular mechanisms regulating CD13-mediated adhesion

(2014) Mallika Ghosh et al.   IMMUNOLOGY

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

(2013) L. Malcovati et al.   BLOOD

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study

(2012) M. G. Della Porta et al.   HAEMATOLOGICA

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

(2012) T M Westers et al.   LEUKEMIA

Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment

(2012) L. Guzman-Rojas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy

(2011) Shikhar Aggarwal et al.   BRITISH JOURNAL OF HAEMATOLOGY

Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System

(2011) Julie Schanz et al.   JOURNAL OF CLINICAL ONCOLOGY

Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes

(2011) Sung-Chao Chu et al.   LEUKEMIA RESEARCH

Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias

(2010) Jevon A. Cutler et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment

(2009) T. M. Westers et al.   BLOOD

Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML

(2009) Monique Terwijn et al.   EUROPEAN JOURNAL OF CANCER

Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study

(2009) K. Ogata et al.   HAEMATOLOGICA

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

(2009) A. A. van de Loosdrecht et al.   HAEMATOLOGICA

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome

(2008) B. L. Scott et al.   BLOOD

The moonlighting enzyme CD13: old and new functions to target

(2008) Paola Mina-Osorio   TRENDS IN MOLECULAR MEDICINE

The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes

(2007) I. Lorand-Metze et al.   LEUKEMIA RESEARCH